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Abstract
Background: Syphilis in pregnancy imposes a significant global health and economic burden. More than half of cases result
in serious adverse events, including infant mortality and infection. The annual global burden from mother-to-child
transmission (MTCT) of syphilis is estimated at 3.6 million disability-adjusted life years (DALYs) and $309 million in medical
costs. Syphilis screening and treatment is simple, effective, and affordable, yet, worldwide, most pregnant women do not
receive these services. We assessed cost-effectiveness of scaling-up syphilis screening and treatment in existing antenatal
care (ANC) programs in various programmatic, epidemiologic, and economic contexts.
Methods and Findings: We modeled the cost, health impact, and cost-effectiveness of expanded syphilis screening and
treatment in ANC, compared to current services, for 1,000,000 pregnancies per year over four years. We defined eight
generic country scenarios by systematically varying three factors: current maternal syphilis testing and treatment coverage,
syphilis prevalence in pregnant women, and the cost of healthcare. We calculated program and net costs, DALYs averted,
and net costs per DALY averted over four years in each scenario. Program costs are estimated at $4,142,287 – $8,235,796 per
million pregnant women (2010 USD). Net costs, adjusted for averted medical care and current services, range from net
savings of $12,261,250 to net costs of $1,736,807. The program averts an estimated 5,754 – 93,484 DALYs, yielding net
savings in four scenarios, and a cost per DALY averted of $24 – $111 in the four scenarios with net costs. Results were robust
in sensitivity analyses.
Conclusions: Eliminating MTCT of syphilis through expanded screening and treatment in ANC is likely to be highly cost-
effective by WHO-defined thresholds in a wide range of settings. Countries with high prevalence, low current service
coverage, and high healthcare cost would benefit most. Future analyses can be tailored to countries using local
epidemiologic and programmatic data.
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Introduction
Syphilis in pregnancy is an under-recognized problem that
carries a significant public health and economic burden. Each
year, nearly 1.5 million pregnant women around the world are
infected with probable active syphilis [1]. According to a recent
meta-analysis [2], over half of untreated pregnancies affected by
syphilis result in adverse outcomes known collectively as mother-
to-child transmission (MTCT) of syphilis. These include stillbirth
and second or third trimester fetal loss (21%), neonatal death (9%),
premature and low birth-weight infants (6%), and infants with
clinical syphilis infection (16%) [2]. The current global burden of
disease attributable to MTCT of syphilis is estimated at 3.6 million
disability-adjusted life years (DALYs), comparable to MTCT of
HIV [1]. Annual global direct medical costs for MTCT of syphilis
total an estimated $309 million [1].
Screening and treatment for syphilis in pregnancy is relatively
simple and inexpensive, and has been shown to be cost-effective
even in low-resource settings [3–7]. New technologies, such as
point-of-care tests, can be used regardless of limited infrastructure
and allow for diagnosis and treatment at a single visit [8].
Treatment with penicillin is inexpensive, and if diagnosed early, is
highly effective in preventing adverse pregnancy outcomes
associated with syphilis in pregnancy [9].
Despite this promising potential for intervention, screening and
treatment of syphilis in pregnancy is not yet universal. Policies on
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screening exist in many countries, but partial or poor program-
matic implementation means that more than 60% of pregnant
women do not receive screening, or receive it too late for
treatment to be effective [10,11]. To address this problem, in
2007, World Health Organization (WHO) began an initiative to
eliminate global MTCT of syphilis, promoting the fundamental
elements of advocacy, political commitment, as well as monitoring,
scale-up and integration of syphilis interventions into existing
antenatal care (ANC) and prevention of MTCT of HIV programs
[12]. The initiative aims to ensure that at least 90% of pregnant
women are screened for syphilis, and 90% of those identified with
syphilis are treated appropriately.
The objective of this study was to model the incremental cost-
effectiveness of scaling-up syphilis screening and treatment in
existing ANC programs. We examined systematically varied
country case scenarios in order to portray results for diverse
programmatic, epidemiologic, and economic contexts.
Methods
Ethics statement
An ethics statement was not required for this work.
Overview
Using a Microsoft Excel model, we analyzed the cost, health
impact, and cost-effectiveness of expanded syphilis screening and
treatment in antenatal care, compared to the current level of
services, for eight generic country case scenarios. We examined
cohorts of 1,000,000 pregnancies per year, for four years. The
four-year time frame was chosen as it represents WHO’s proposed
initial duration of intensified support for MTCT of syphilis
elimination of countries, though we would hope that these efforts
would continue past these four years. For the cost analysis, we
assessed the direct medical costs of implementing expanded testing
and treatment of syphilis in pregnancy. For the health impact
analysis, we estimated the health benefits of an expanded program
in terms of averted clinical adverse outcomes and DALYs. The
cost-effectiveness analysis was adjusted for offsetting savings due to
replaced programming and averted adverse outcomes, and
calculated incremental cost-effectiveness ratios as the cost per
DALY averted. We used a societal perspective; discounted long
term costs and DALYs at 3% per year; and expressed results in
2010 US dollars. Table 1 summarizes input assumptions.
Country case scenarios
Based on published and empirical evidence, we generated
plausible generic country scenarios in order to describe results for
a wide range of potential intervention settings. This approach
avoids the complexities and nuances of local data, which we
believe are best addressed as part of individual country analyses
rather than a global view.
We selected three contextual factors predictive of the incre-
mental cost and impact of scaled-up syphilis screening and
treatment: current syphilis testing and treatment coverage in ANC,
prevalence of syphilis among pregnant women attending ANC,
and the relative cost of health services. We assigned plausible high
and low values to each factor. Varying these three dichotomous
factors together produced eight combinations and thus eight case
scenarios, e.g., Country A: high current service coverage, high
prevalence, and high cost; Country B: low current service
coverage, high prevalence, and high cost; etc. The scenarios are
summarized with the results in Table 2. Using publicly available
data on ANC syphilis prevalence [13], ANC syphilis testing [14],
and health care service costs [15], we created a table matching
countries to each of the eight scenarios in order to help
contextualize the generic scenarios (Table S1).
The high and low values for each factor were defined as follows;
further variation around the scenario-defining values is examined
in sensitivity analyses:
The current coverage of syphilis testing and treatment in ANC
reflects the percentage of women in ANC who receive both testing
and treatment to prevent MTCT of syphilis. We varied this factor
from a low of 20% to a high of 70% [1] to reflect regional
variations in current ANC capacity, syphilis screening policies, and
implementation of those policies [10].
The prevalence of syphilis among pregnant women attending
ANC was defined as the percentage of women attending ANC
with a reactive test result based on a syphilis serological test. We
varied this factor from a low of 0.5% to a high of 3% [1].
We defined the cost of health services as the relative cost of
comparable health services based on WHO CHOICE unit cost
data [16]. For inpatient care, we specified the relative unit cost
differential between the country for which we obtained cost data
(South Africa)[6] and lower cost countries as 1 to 0.25. For
outpatient care, the analogous ratio in WHO CHOICE is 1 to
0.75.
Inputs and assumptions
Burden of disease: MTCT of syphilis adverse outcomes in
the absence of syphilis screening or treatment. From the
literature, approximately 65% of pregnant women with reactive
syphilis serologic tests have probable active syphilis, i.e., infections
with reactive treponemal as well as non-treponemal (e.g., RPR)
serologic tests, suggesting potential for MTCT of syphilis to occur
[17–19]. Thus, we calculated a prevalence of active syphilis of
0.33%–1.95% across the scenarios. A recent meta-analysis
estimated that 52% of pregnancies among women with untreated
active syphilis infection result in adverse outcomes for the infant
caused by syphilis [2]. Therefore, for 1,000,000 pregnancies per
year in our analysis, in the absence of syphilis screening or
treatment an estimated 1,697 MTCT of syphilis adverse outcomes
(AOs) would be expected in low syphilis prevalence settings, and
10,179 AOs in high syphilis prevalence settings (6,786 – 40,716
AOs over four years).
Burden of disease: MTCT of syphilis adverse outcomes
assuming current levels of screening and treatment. With
partial implementation of syphilis screening and treatment in ANC
(20% in low and 70% in high coverage settings), and a treatment
efficacy of 90% (based on published evidence,[9,20] and assuming
a certain percentage of women receive treatment after the period
of maximum efficacy), we estimated between 305 – 6,413 AOs
would be averted per country per year with the current level of
services.
Burden of disease: MTCT of syphilis adverse outcomes
with expanded screening and treatment. Based on the
proportion of pregnant women screened and treated at the current
level of services, we made the following assumptions about an
expanded screening and treatment program. In low coverage
settings (currently 20% screened and treated), we assumed that
70% of pregnant women would attend ANC services, of whom
80% would receive syphilis testing, and 90% of those with a
reactive test would receive treatment. Though the goals for the
MTCT of syphilis elimination initiative are for 90% of pregnant
women to be screened and 90% of syphilis reactive cases to be
treated by 2015, we conservatively assumed a lower percentage
would be screened in current low coverage settings, due to lower
baseline levels of testing and treatment. In high coverage settings
(currently 70% screened and treated), we assumed 95% of
Cost-Effectiveness of Maternal Syphilis Screening
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Table 1. Base Case Inputs and Assumptions.
BC value*
Input LO HI One-way SA range** Source/Notes
Cohort size 1,000,000 n/a Assumption
Discount rate 3% n/a
Pr. active syphilis in women with
a reactive syphilis serological test
65% 50% – 80% [17–19]
Pr. reactive syphilis serological test
in pregnant women
0.5% 3.0% HI: 3.0% – 6.0% Assumption
Test sensitivity of RPR 100% 70.7 – 100% [34]
Current % tested and treated 20% 70% LO: 10% – 40% HI: 50% – 72% Assumption
Health service cost level (inpatient) 0.25 1 LO: 0.10 – 0.33 WHO CHOICE [16]
Health service cost level (outpatient) 0.75 1 LO: 0.20 – 0.75 WHO CHOICE [16]
Intervention characteristics
% Attending ANC 70% 95% LO: 60% – 80% HI: 90% – 99% Assumption
% Screened 80% 90% LO: 70% – 90% HI: 85% – 99% Assumption
% Treated 90% 95% LO: 80% – 95% HI: up to 99% Assumption
Treatment performance 90% 70% – 99% [20]; decreasing efficacy with later treatment
(Hawkes, unpublished)
AO incidence (no intervention)
All AO 52% 40% – 70% [2]
Stillbirth/2nd/3rd trimester fetal loss 20.9% 16.2% – 28.3% Proportional incidence
Neonatal death 9.3% 7.3% – 12.7% Proportional incidence
Infected infant 15.5% 11.9% – 21% Proportional incidence
Prematurity or low birth weight 5.8% 4.6% – 8% Proportional incidence
Adult syphilis averted per syphilis
positive pregnancy treated
1 0 – 1 Assumption
HIV cases averted per syphilis positive
pregnancy treated
0.001 0 – 0.001 [24]
DALYs
Stillbirth/2nd/3rd trimester fetal loss 4.95 0 – 30 [22]; Assumption
Neonatal death 9.4 0 – 30 [22]; Assumption
Infected infant 9.48 6 – 15 [22]; Assumption
Prematurity or low birth weight 3.18 1.59 – 4.77 [22]; Assumption
Adult STI (HIV and syphilis) 1.34 0.67 – 2.01 [22]; Assumption
HIV 7.2 4.75 – 9.5 [35]
Costs{
Stillbirth/2nd/3rd trimester fetal loss $0 - $1̂ n/a [6]
Neonatal death $893 $3,571 n/a [6]
Infected infant $182 $243 n/a [6]
Prematurity or low birth weight $366 $1,464 n/a [6]
Primary syphilis $15 $20 n/a Based on single visit, test, PCN
Secondary & early latent syphilis $15 $20 n/a Based on single visit, test, PCN
Late latent & tertiary syphilis $500 $2,000 n/a U.S. est. [36] adjusted for lower price and
incidental treatment in developing countries and
inpatient unit costs [16]
HIV infection $6,500 n/a [35]
Syphilis test with labor & supplies $1.83 $2.30 LO: $1.48–$2.22 HI: $1.82–$2.56 WHO Bulk Procurement and IDA Foundation
estimates (unpublished data, 2012) [6]
Cost-Effectiveness of Maternal Syphilis Screening
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pregnant women attend ANC services, of whom 90% would
receive testing, and 95% of those with a reactive test would receive
treatment. Therefore, under the expanded program, these
assumptions would translate to an increase from current coverage
levels of 20% to 50.4% of women tested and treated in low
coverage settings, and an increase from 70% to 81.2% in high
coverage settings. In the base case, we assume an RPR sensitivity
of 100%; however RPR sensitivity may vary based on the stage of
syphilis at the time of diagnosis. We test the robustness of this
assumption in sensitivity analysis.
We calculated the expected net AOs averted over four years as
the product of the number of AOs in the absence of treatment and
the increase in syphilis screening and treatment coverage from
current to expanded services, assuming 90% treatment efficacy
[9,20]. Using published data on the rates of each AO in untreated
pregnancies, we then calculated the numbers of each specific AO
averted under the expanded program.
Burden of disease: DALYs. A DALY is a summary measure
of disease burden that combines, for a specific disease or condition,
the number of years of life lost due to premature mortality (YLLs)
with that of years of life lost due to disability (YLDs) [21]. The
numbers of DALYs associated with each AO were derived from
estimates in the 2006 Global Burden of Disease [22], as described
below.
We assumed a stillbirth causes 4.95 DALYs and a neonatal
death causes 9.4 DALYs – conservative assumptions based on a
3% discount rate, uniform age weights, and a gradual acquisition
of life potential (ALP; i.e., that deaths that occur at very young
ages (,5 years) carry less weight than those that occur later in
childhood, with the number of years of life lost gradually
increasing from deaths occurring near the time of birth to deaths
occurring at the age of 5) [23]. Though previous assessments of the
global burden of disease have not included stillbirths, Jamison and
colleagues have suggested the incorporation of ALP as a way to
include and flexibly weight stillbirths and other early deaths when
assessing disease burden [23].
We assumed an infant born with low birth weight and an infant
infected with syphilis carry DALY burdens of 3.18 and 9.48,
respectively, based on disability weights of 0.106 and 0.316,
respectively [22], applied to the 30 discounted life year potential of
a normal lifespan. We calculated the expected DALYs averted in
fetuses and infants over the four years of the expanded program as
the product of the number of each AO and the DALYs associated
with that AO.
Given the dynamics of syphilis transmission, it is plausible that
syphilis treatment may avert additional cases, though data are
lacking on the number of cases averted per case of syphilis treated.
In the base case, we assumed that each case of treated syphilis in
pregnancy would avert one case of adult syphilis. In sensitivity
analysis, we explored the effect on cost-effectiveness of a more
conservative assumption, with modified estimates of 0.5 cases and
0 cases averted per case of syphilis treated (see Text S1 for details).
Syphilis is a sexually transmitted infection, and infection with
syphilis increases the risk of HIV transmission and acquisition
[24,25]. We assumed that treating syphilis in pregnancy has a
modest effect in reducing syphilis-attributable HIV cases, and that
treatment would avert 0.759 DALYs on average (the weighted
mean DALYs from adult syphilis and HIV; see Text S1 for
details).
The expected net DALYs averted over the four years of the
MTCT of syphilis elimination program was calculated as the sum
of the DALYs averted in fetuses and infants and those due to
reduced STI in adults.
MTCT of syphilis elimination program cost. Under the
new initiative, we assumed universal use of a syphilis serological
test for screening and diagnosis of syphilis in ANC. We calculated
the cost of the program for four years as the costs of testing (i.e.,
the syphilis test kit and the cost of labor and supplies), plus the
costs of treatment for seropositive women (i.e., counseling and a
three-dose course of penicillin). While a single dose of penicillin is
sufficient to treat pregnant women with primary, secondary and
early latent syphilis, three doses are recommended for the
treatment of late latent syphilis [26], and we conservatively
assumed universal use of a three-dose course. We explored the
effect on costs of using a single dose of penicillin in a sensitivity
analysis. The prices of a syphilis serological test (specifically, an
RPR test) and a three-dose course of long-acting, intramuscular
penicillin were determined from the WHO bulk procurement
system, with allowances for delivery costs (WHO, unpublished
data, 2012). The RPR test, with transport, was calculated as $0.21
(the cost of one test from a kit of 100) plus $0.21 (the cost of
airfreight, packaging and insurance per test, based on an order of
2100 tests at $450 total transport costs). The three-dose course of
penicillin was calculated based on a price of J34.82 per 50-vial
Table 1. Cont.
BC value*
Input LO HI One-way SA range** Source/Notes
Course of benzathine penicillin
(3 doses) including counseling
$3.72 $3.79 LO: $1.39–$3.72 HI: $1.46–$3.79 WHO Bulk Procurement estimates (unpublished
data, 2012); [6]
*Low and high values of the base case are provided for inputs that vary based on the country case scenario. Each case scenario is characterized by low or high values on
three factors: the prevalence of a reactive syphilis serological test in pregnant women, the percentage of women tested and treated for syphilis in ANC at the current
level of services, and the relative cost of health services (including the cost of PMTCT of syphilis AOs). Accordingly, the percentages of women attending ANC and tested
and treated for syphilis under the expanded program vary by case scenario, as do the costs of syphilis AOs and of screening and treating syphilis in the mother. All other
base case inputs are constant across the eight case scenarios.
**Two sensitivity analysis ranges (high and low) are provided for inputs that vary based on the country case scenario. For all other inputs explored in SA, a single range
is given
{For each MTCT of syphilis AO we estimate the cost by subtracting the cost of the healthy childbirth from the cost of the AO; this might be overestimate the benefits of
preventing MTCT of syphilis as it assumes that all infants would otherwise be born healthy.
ˆNegative costs imply savings. Based on published data from South Africa, the cost of delivery of a stillborn infant was assumed to approximate the cost of delivery of a
healthy infant (i.e., $58), and the cost of a spontaneously aborted pregnancy was ,$57). We estimated the cost of a stillbirth/2nd/3rd trimester fetal loss as the cost of a
spontaneously aborted pregnancy minus the cost of a normal delivery (what the cost would have been in the absence of the AO), i.e., 2$1. In settings where the cost of
health care services is high, the estimate is 2$1, and in those where the cost of services is low, the estimate is $0 (because of the adjustment for the cost per hospital
day).
doi:10.1371/journal.pone.0087510.t001
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box (converted to USD at 1.25 conversion), with 30% added cost
for shipping, and $3.30 per box of 100 sterile water vials for
reconstitution.
Though we used the cost of an RPR test in the base case
analysis, use of a rapid diagnostic test (RDT) –another type of
syphilis serological test– would have resulted in a very similar cost
estimate when factoring in additional components such as
transport, labor and supplies. The WHO bulk procurement
system cost of the RDT including transport was calculated as
$0.40 (the cost of one test from a kit of 25) plus $0.07 (the cost of
airfreight, packaging and insurance per test based on an order of
10,000 tests at $740 total transport cost). Including labor and
supplies[6] the total estimated cost of an RDT is $1.82 versus
$2.30 for an RPR (based on WHO bulk procurement system
quotes); using price quotes from the IDA Foundation, the total
estimated cost of an RDT is $2.56 versus $2.02 for the RPR,
yielding overlapping ranges for these two types of syphilis
serological tests (RPR: $2.02 – $2.30; RDT: $1.82 – $2.56). We
explored a plausible range of syphilis serological test costs in
sensitivity analysis.
The costs of labor and supplies, and the cost of syphilis
counseling were derived from an analysis using costs from South
Africa[6]. Using WHO CHOICE unit cost data[16], we adjusted
the costs of testing and treatment across country scenarios based
on constant commodity costs (test kits and penicillin) and the
relative cost of outpatient care (described above). The overall cost
of testing across the scenarios was $1.83 – $2.30 per woman, and
of treatment with a three-dose course of penicillin was $3.72 –
$3.79.
Cost of AOs. The cost of each MTCT of syphilis AO was
derived from two studies using costs from South Africa[5,6], which
estimated the cost of hospitalization for treatment. All costs were
adjusted to 2010 US dollars using an inflation rate of 4% per year,
and then further adjusted based on the cost level (cost per hospital
day) in that country scenario (i.e. by 0.25 in low cost countries, and
by 1.00 in high cost countries). The cost of delivery of a stillborn
infant was assumed to approximate the cost of delivery of a healthy
infant (i.e., $58), and the cost of a spontaneously aborted
pregnancy was ,$57). We estimated the cost of a stillbirth/fetal
loss as the cost of a spontaneously aborted pregnancy minus the
cost of a normal delivery (what the cost would have been in the
absence of the AO), i.e., 2$1. In settings where the cost of health
care services is high, the estimate is 2$1, and in those where the
cost of services is low, the estimate is $0 (because of the adjustment
for the cost per hospital day). For the estimate of the cost of
treatment for an infant infected with clinical syphilis, we assumed
that 30% of cases would be discovered and treated based on
clinical findings.
Offsetting savings from MTCT of syphilis elimination
program. While the program carries a cost for expanded
screening and treatment, savings are accrued due to averted
MTCT of syphilis AOs and averted adult sexually transmitted
infections (STIs) (syphilis and HIV). Moreover, since at least a low
level of maternal syphilis services are available in each of the
country scenarios under consideration, we assumed that the prior
services would be replaced by the new program and we adjusted
the cost of the expanded program accordingly.
We calculated the savings due to net averted MTCT of syphilis
AOs as the combined cost of each AO times the number of each
AO prevented under the program.
We calculated the savings due to net averted adult syphilis and
HIV cases as the number of adult STIs prevented under the





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cost-Effectiveness of Maternal Syphilis Screening
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e87510
weighted mean of serious cases (tertiary syphilis and HIV) and
mild cases (primary and secondary syphilis).
We assumed equivalence in the intensity of existing versus new/
expanded services, i.e., no enhancements other than the expansion
of existing screening and treating activities. We calculated the cost
of the prior maternal syphilis services as the cost of the new
program times the ratio of the proportion tested and treated under
the current level of coverage versus under the expanded program.
Sensitivity analyses
In order to assess the influence of variations in the value of key
model inputs on cost-effectiveness within each generic country
scenario, we performed one-way sensitivity analyses on 20
variables. For the base case country scenarios, we defined a high
prevalence of syphilis among pregnant women in ANC of 3%; this
represents a plausible value based on empirical evidence from
various countries. However, some published studies have reported
prevalence estimates exceeding this value [27]. Therefore, we
explored the effect of increasing the population prevalence of
syphilis to 6% in sensitivity analysis. Additional variables explored
related to the impact of the intervention included: the prevalence
of active syphilis among pregnant women with a reactive syphilis
serological test, test sensitivity of the RPR, current coverage of
syphilis testing and treatment among ANC attendants, health
service cost level (inpatient and outpatient), expected coverage of
syphilis testing and treatment among ANC attendants in the
intervention scenario, treatment performance, incidence of
adverse pregnancy outcomes in untreated pregnancies, the
expected number of adult syphilis cases averted for each syphilis
positive pregnant woman treated, and the number of adult HIV
infections averted per adult syphilis infection treated. We also
included in the sensitivity analysis the cost of the syphilis
serological test, the cost of a course of penicillin (where we assume
a single dose instead of 3 doses of penicillin is used [28]), and all
DALY estimates (i.e., the number of DALYs per infant infected
with syphilis).
The ranges used for the sensitivity analysis are presented in
Table 1. Results are displayed in modified spider diagrams
showing effects on net costs and DALYs averted.
Finally, in order to test the combined effect of uncertainty in
basic assumptions that were unrelated to the intervention, we
performed four two-way sensitivity analyses. The inputs varied in
these four analyses are: 1) DALYs associated with stillbirth, and
adverse outcome incidence without treatment, 2) treatment
performance, and adverse outcome incidence without treatment,
3) treatment performance, and adult syphilis averted per syphilis
positive pregnancy treated, and 4) percentage of active syphilis
among pregnant women with a reactive syphilis serological test,
and adverse outcome incidence without treatment. We used the




In the eight country scenarios, we estimate between 686 –
11,140 MTCT of syphilis AOs would be averted over four years
with the expanded program, including 278 – 4,521 stillbirths, 124
– 2,012 neonatal deaths, 206 – 3,353 infected infants, and 77 –
1,255 premature or low birth weight infants. When factoring in
adult syphilis and HIV cases that would be averted by treating
cases of maternal syphilis, this translates to 5,754 – 93,484 DALYs
that would be averted across the eight case scenarios.
Table 2 and Figure S1 present the cost, health impact, and cost-
effectiveness findings for the base case values in the eight country
settings. The estimated four-year cost of the expanded testing and
treatment program ranges from $4,142,287 – $8,235,796 (2010
US dollars), assuming 1,000,000 pregnant women per year. When
adjusted for offsetting savings due to averted AOs and replaced
current services, net incremental costs range from net savings of
$12,261,250 to a net cost of $1,736,807. Net savings are achieved
in all four of the high prevalence country scenarios.
The MTCT of syphilis elimination program averts an estimated
5,754 – 93,484 DALYs over four years in the eight scenarios,
yielding a cost-effectiveness ratio of $24 – $111 per DALY averted
in the four scenarios with net costs. In the remaining four country
scenarios, the program is cost saving, or dominant (more effective
and less expensive as compared to the baseline); i.e., the
intervention pays for itself in offset medical costs so no cost-
effectiveness (CE) ratio needs to be calculated.
Sensitivity analyses
Results for one-way sensitivity analyses within scenarios are
presented in Figure 1 (net cost and DALYs) and in Table S2 (net
cost, DALYs, and CE ratios). Since the basic structure of the
analysis presented in this article is a 3-way sensitivity analysis
(three dichotomous factors generating 8 scenarios), these one-way
factor variations test the robustness of each scenario.
In high syphilis prevalence scenarios (country scenarios A
through D), the intervention remains cost saving across nearly all
sensitivity analysis values; reducing the relative inpatient cost
differential between South Africa and lower cost countries to 0.10
slightly worsens the cost-effectiveness ratio in scenario A (from
cost-saving to $1/DALY averted). Increasing the background
syphilis prevalence significantly increases the savings and benefits
of the intervention. The net savings and DALYs averted move in
tandem (essentially as a scale effect) according to the current
coverage of testing and treatment, the coverage gain, and the risk
of adverse events without treatment. Total DALYs averted, but
not costs, are sharply affected by DALYs associated with stillbirth.
Uncertainty in other factors has smaller effects.
In low prevalence scenarios (country scenarios E through H),
the intervention remains highly cost-effective across all input
variations. The intervention becomes cost saving in two country
scenarios (F and H) when modifying two inputs: the prevalence of
active syphilis among pregnant women with a reactive syphilis
serological test (from 65% to 80%) and the cost of a syphilis
serological test (from $2.30 to $1.82). Overall, however, there is
much less absolute variation in costs and DALYs than in scenarios
A through D (Figure 1). This is because the prevalence of syphilis is
six times lower, so that proportionate changes in other factors (e.g.
rise in coverage) modifies a much smaller base case result.
While lowering the inpatient cost ratio slightly worsens cost-
effectiveness, lowering the outpatient cost ratio slightly improves
cost-effectiveness. Lowering both the inpatient and outpatient cost
level in tandem balances out the effect of each, yielding results
more closely resembling the base case.
Switching from a three-dose course of penicillin to a single dose
has a negligible effect on the cost-effectiveness of the expanded
program (with the cost per DALY averted in the low prevalence
scenarios changing from $24–$111 to $23–$111). This is under-
standable since the program is already cost saving in high
prevalence scenarios, and only a small proportion of women
require treatment in low prevalence scenarios.
The results are relatively sensitive to five main assumptions
(detail in Table S2). The input with the greatest influence on cost-
effectiveness is the sensitivity of the RPR test. If we assume that the
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RPR test has a sensitivity of 70.7%, the intervention remains cost
saving in the four high-prevalence scenarios, and in the four low-
prevalence scenarios the cost per DALY averted ranges from
$103–$177 (compared to $24–$111 in the base case). Cost-
effectiveness is also sensitive to the assumption of the horizontal
spread of syphilis. If we assume that treatment of syphilis in
pregnancy has a lesser effect on horizontal syphilis transmission
than assumed in the base case (i.e., averts either 0.5 or 0 cases of
adult syphilis instead of 1 case at baseline), the results are
somewhat less favorable but remain qualitatively the same (see
Text S1). Assuming zero cases of adult syphilis averted per case
treated, the cost per DALY averted increases to $103–$157 for the
intervention in the four low-prevalence scenarios (compared to
$24–$111 in the base case). Cost-effectiveness is similarly sensitive
to the risk of adverse events without treatment. The CE ratio is
also very sensitive to the DALYs per stillbirth. Cost and DALY
results are sensitive to scale factors such as the gain in coverage,
but tend to rise and fall together, such that the CE ratio is
relatively unaffected by these factors. Other factors, such as
proportion of syphilis in pregnant women, have smaller magnitude
effects on all outcomes.
Results for two-way sensitivity analyses within scenarios are
presented in Table S3 (net cost, DALYs, and CE ratios). Varying
the cases of adult syphilis averted per syphilis positive pregnancy
treated (from 1 down to 0 cases) in tandem with the treatment
performance (from 0.9 down to 0.7) yields the greatest effect on
cost-effectiveness. In scenarios B and D, the intervention remains
cost saving, though in scenarios A and C, the intervention changes
from cost saving to carrying a cost per DALY averted of between
$4–$6 per DALY averted. In the four low-prevalence scenarios,
the cost per DALY averted increases to $133–$207 per DALY
averted (compared to $24–$111 in the base case).
In the remaining two-way sensitivity analyses, varying the
factors down to the minima in the ranges has no qualitative effect
on the cost-effectiveness ratio in scenarios A through D (remains
cost saving). In scenarios E through G, the cost-effectiveness ratio
worsens slightly when the factors are lowered to their minima;
however, varying the factors up to their maxima improves cost-
effectiveness and the intervention becomes cost saving in scenarios
F and H.
Discussion
We found that eliminating congenital syphilis through an
expanded screening and treatment program in antenatal care
facilities would be cost saving in four of eight country scenarios
examined. In the other four scenarios, the cost per DALY averted
ranges from USD $24 – $111. According to the World Health
Organization, an intervention is ‘‘cost-effective’’ if it costs up to
three times the per-capita GDP of a country and is ‘‘highly cost-
effective’’ if it costs less than the per capita GDP[29]. By WHO
standards, therefore, the MTCT of syphilis elimination program
can be considered highly cost-effective in all of the scenarios we
explored, given that all countries have a per-capita GDP of at least
$111 [30]. Although the cost-effectiveness results were calculated
per one million pregnancies, the results are expected to scale,
leaving the cost per DALY averted unchanged for countries of
different sizes.
The four country scenarios in which the initiative would be cost
saving are all high prevalence settings (i.e., prevalence of a reactive
syphilis serological test in pregnancy of 3%). Though the cost of
the program is roughly comparable to that in low prevalence
((0.5%) settings, high prevalence settings would be expected to
achieve higher offsetting savings due to greater net averted disease
costs. However, even in low prevalence settings, the program
would be expected to avert approximately $300,000 – $2.6 million
in medical costs from MTCT of syphilis and adult STI adverse
outcomes. While the initiative is cost saving, or at least highly cost-
effective, in all of the country scenarios examined, the most
favorable findings (i.e., lowest net cost and highest number of
DALYs averted) were observed in the scenario with a high
maternal prevalence of test-positive syphilis, low level of current
testing and treatment, and high service cost level. This is
understandable considering countries that currently test and treat
only a small proportion of ANC attendees would stand to benefit
most from an expanded program. Moreover, countries in which
the cost of medical services is high would be expected to pay more
to treat AOs, and would see higher savings from averted disease
costs in the MTCT of syphilis elimination program.
In addition to being cost-effective, integrating an expanded
screening and treatment program into existing ANC and
prevention of MTCT of HIV programs has been shown to be a
feasible and efficient way to reduce the burden of MTCT of
syphilis, and infant mortality and morbidity in general [4,31].
Though attendance at ANC varies greatly, more than three-
quarters of all pregnant women globally now receive at least one
antenatal care visit [32], suggesting that ANC programs are
widespread and generally well accepted. To enhance effectiveness,
elimination programming should be coupled with a strong
marketing/outreach component to promote early access to
ANC, since this is the period of maximum effectiveness for
maternal syphilis treatment [9]. An integrated program that
focuses on early access to services would build on existing efforts to
improve the quality of antenatal care, strengthening and
maximizing the ability of these programs to improve maternal
health and reduce infant mortality.
There are a few important limitations to this analysis. First, we
did not model cost-effectiveness in specific countries, but rather in
hypothetical scenarios with a pre-determined set of characteristics
related to prevalence, care coverage, and health care services cost
(see Table S1 for countries resembling the eight hypothetical
scenarios). Given the varied priorities and resource constraints in
many countries, it will be important for health care entities to
assess the cost-effectiveness of expanded syphilis screening and
treatment within existing ANC services under their specific set of
country characteristics. One way to do this is to adapt modeling
techniques, such as those used in this study, to the context of
individual countries through the use of national data and targets
[33]. Nonetheless, by modeling cost-effectiveness in eight different
scenarios, this analysis presents findings that are likely robust over
a wide range of settings.
Second, when quantifying the cost of AOs, we included only the
direct medical costs of care and treatment. We did not include
indirect costs, such as lost productivity, and special educational
needs of infants with syphilis infection, since such costs are very
difficult to quantify. However, including these costs would have
Figure 1. Sensitivity of net cost and DALYs averted to uncertainty in 20 key inputs. Costs are in 2010 USD. Eight country scenarios (A–H)
are represented in panels. Scenarios A–D are high syphilis prevalence (3% in the base case), and scenarios E–H are low syphilis prevalence (0.5% in the
base case). In scenarios A–D, the intervention remains cost saving across almost all sensitivity analysis values. In scenarios E–H, the intervention
remains at least highly cost-effective across all input variations.
doi:10.1371/journal.pone.0087510.g001
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made the cost-effectiveness estimates of the initiative even more
favorable. Third, given the range of syphilis serological tests and
the absence of quantitative or confirmatory tests in most low-
income countries, we made a simplifying assumption that 65% of
positive serologic tests reported in surveillance were true positives.
This was based on two types of data from studies in low-income
settings: the positive predictive value of a rapid test against a gold
standard of laboratory based RPR and VDRL [17,18]; and the
proportion of RPR positive tests with a titer of at least 1:8 [19].
This titer suggests sufficient treponemal load for vertical transmis-
sion and excludes most serofast or biologic false positive tests.
Future analyses would benefit from explicit modeling of test
sensitivity and specificity. Fourth, we assumed treatment with
penicillin would be based on a reactive serological test, and we did
not attempt to estimate the health impact of any potential side
effects of treatment for women who are biologically false positive.
However, penicillin has no known negative impact on pregnancy
in women without penicillin allergy, and common side effects such
as diarrhea have small DALY effects when weighed against the
benefits of prompt treatment before a confirmatory test.
Finally, the value of some of the inputs was uncertain due to a
scarcity of data in the literature (i.e., the cost of primary syphilis).
Where data were lacking or imperfect, we made adjustments or
assumptions for base case values, and performed multiple one-way
sensitivity analyses and four two-way sensitivity analyses over a
range of input values. For example, in the base case, we assumed a
DALY benefit from treatment due to reduced AOs in the infant
and reduced STIs in adults. Since the benefits to the index patient
and others in terms of reduced adult STIs are uncertain, we
performed sensitivity analysis to explore the effect of a lesser
influence of treatment on horizontal transmission. Even assuming
no DALY benefits in adults from treatment, the results remain
qualitatively similar. Indeed, the MTCT of syphilis elimination
program remained cost saving or highly cost-effective across all of
the inputs explored.
Our analysis suggests that integrating expanded syphilis
screening and treatment into ANC programs would be cost saving
or highly cost-effective in all scenarios examined. Countries with
high maternal syphilis prevalence, low current service coverage,
and high healthcare cost would likely benefit most. Future analyses
can be tailored to specific countries using local epidemiologic and
programmatic data. Based on realistic assessments of human
resource and infrastructure capacity, specific targets for screening
and treatment within existing ANC services will be needed to
assess progress on a country level. Country-specific targets for
impact indicators, such as the rate of stillbirths and the rate of
clinical syphilis, will also be needed to assess the program’s
progress towards the goal of elimination of MTCT of syphilis.
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Figure S1 Intervention cost and net incremental cost of
scaled-up screening and treatment for MTCT syphilis
prevention. Costs are in 2010 USD. Intervention cost and net
incremental cost (savings) are presented for country scenarios A–
H. Scenario factors on the horizontal axis: Prevalence of syphilis
by serological testing (high prevalence = 3%; low prevalence =
0.5%); Coverage of current syphilis screening and treatment in
ANC (high coverage = 70%; low coverage = 20%); Cost of health
services (i.e., health care cost structure, including the cost of
MTCT of syphilis AOs; high cost = 1; low cost = 0.25 based on
WHO CHOICE data (http://www.who.int/choice/en/). Imple-
menting expanded testing and treatment of syphilis in ANC
generates net savings in settings with high maternal syphilis
prevalence (3%), especially in scenarios where the cost of care and
treatment is high. In settings with low maternal syphilis prevalence
(0.5%), the intervention yields net costs of ,$140,000 – $1.7
million. Net costs are substantially lower than intervention costs
due to the offsetting savings resulting from averted MTCT of
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prior syphilis testing and treatment services replaced by the
expanded program.
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